CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 138 filers reported holding CLOVIS ONCOLOGY INC in Q1 2014. The put-call ratio across all filers is 0.69 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $7,000 | -36.4% | 1,590 | -21.9% | 0.00% | 0.0% |
| Q2 2021 | $11,000 | – | 2,035 | +8747.8% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 23 | -92.1% | 0.00% | – |
| Q4 2019 | $3,000 | -70.0% | 290 | -89.3% | 0.00% | -100.0% |
| Q3 2019 | $10,000 | -61.5% | 2,700 | +50.0% | 0.00% | -66.7% |
| Q2 2019 | $26,000 | -82.2% | 1,800 | -35.3% | 0.00% | -76.9% |
| Q1 2018 | $146,000 | -21.1% | 2,781 | -4.5% | 0.01% | -31.6% |
| Q1 2017 | $185,000 | +79.6% | 2,913 | +1.6% | 0.02% | +72.7% |
| Q3 2016 | $103,000 | +139.5% | 2,867 | +129.0% | 0.01% | +57.1% |
| Q4 2015 | $43,000 | -60.2% | 1,252 | +6.1% | 0.01% | -63.2% |
| Q3 2015 | $108,000 | +83.1% | 1,180 | +10.3% | 0.02% | 0.0% |
| Q4 2014 | $59,000 | -86.0% | 1,070 | -89.5% | 0.02% | -71.2% |
| Q2 2014 | $420,000 | +924.4% | 10,150 | +1591.7% | 0.07% | +560.0% |
| Q1 2014 | $41,000 | – | 600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |